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INTRODUCTION:  
Diabetes mellitus is a chronic metabolic disorder 
characterised by high blood glucose level due to insulin 
deficiency. It is a major and still growing health problem 
worldwide. Glipizide is a second generation sulfonylurea 
used as oral hypoglycaemic agent. Glipizide 
(sulfonylureas) provoke release of insulin from pancreas 
by acting on sulfonylurea receptors on the pancreatic ß cell 
membrane. Transdermal patches of glipizide offer an 
advantage of reduced dosing frequency, thus enhancing 
patient compliance. Drug delivery through skin bypasses 
hepatic first pass metabolism which cannot be bypassed in 
oral route. Glipizide is used in NIDDM and acts by 
increasing the release of endogeneous insulin and its 
peripheral effectiveness.12. The present study was aimed at 
development of matrix diffusion controlled transdermal 
patches using different polymers and different penetration 
enhancers. Literature survey revealed that use of HPMC 
5cps17, 18, EC17 and PVP K 3018 as polymers forms matrix 
patches and gives release for more than 10 hours. 
Literature survey also revealed that use of PEG 400 as 
plasticizer produced films with high folding ndurance.18 
MATERIALS AND METHODS: 
Materials:  
Glipizide was received as a gift sample from Ronak 
Pharmaceuticals pvt Ltd., Patan. Eudragit RS 100 was 
received as a gift sample form Roehm Pharma polymers. 
HPMC 5 cps, HPMC 15 cps, PVP K 30, HPMC K 100M, 
Ethyl cellulose, Propylene glycol, PEG 400, n-dibutyl  
 
phthalate, Methanol and Chloroform were purchased from 
Central Drug House (P) Ltd., New Delhi. 
Method:
 7, 11  
Preparation of patches: Matrix type transdermal patches 
loaded with Glipizide were prepared by solvent casting 
method. Required quantities of polymers were weighed 
and dissolved in 10 ml mixture of methanol and 
chloroform in the ratio 1:1. Sonicate for 30 min. Stir for 1 
hour on a magnetic stirrer at 400rpm. 73.88 mg of drug 
was weighed and added to the above solution. Required 
quantity of PEG 400, n-DB (as plasticizers) and propylene 
glycol (as penetration enhancer) were measured and added 
to the above solution. Stir on a magnetic stirrer at 400 rpm 
for 2 hours. The resulted uniform solution was cast on a 
Petri dish of area 66.50 cm2, previously containing a layer 
of mercury. An inverted funnel was placed over the Petri 
dish to prevent the fast evaporation of the solvent. After 24 
hours, the dried patches were taken out, cut into pieces of 
3cm * 3cm (area = 9 cm2 and containing 10mg of the 
Glipizide) and stored in a desiccator. 
EVALUATION: 
1, 2, 7, 11 
1. Weight uniformity: 
The prepared patches are to be dried at 60ºC for 4 
hours before testing. Weight uniformity was done by 
weighing 5 different patches of each batch. All the 
patches, selected at random, should be uniform in 
size (3cm * 3cm). Calculate the average weight of 
three. 
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Table 1: Formulation for Glipizide transdermal patches 
 
2. Thickness of the patch: 
 The thickness of the patch is measured by digital 
micrometer at different points. For each formulation, 
three patches were used. The average value for the 
thickness of single patch was determined. 
3. Folding endurance: 
 A strip of specific area (3cm * 3cm) is to be cut 
evenly and repeatedly folded at the same place till it 
broke. The number of times the film could be folded 
without breaking gave the value of folding 
endurance. 
4. Percentage moisture content: 
 Three patches of the same composition were 
weighed and kept on desiccators containing fused 
calcium chloride at 37ºC until no change in weight of 
the individual patches was observed. This weight was 
noted as the final weight. The percentage moisture 
content was calculated as a difference between 
individual and final weight. An average is shown in 
table-2. 
5. Moisture uptake: 
 To determine the moisture uptake of the patches, 
three weighed patches of the same batch (kept in 
desiccator at 37ºC until constant weight) were 
exposed to two different relative humidity 
conditions: 75% RH (saturated solution of sodium 
chloride) and 93% RH (saturated solution of 
ammonium hydrogen phosphate) respectively at 
room temperature. After 24 hours, the films were re-
weighed and percentage moisture uptake was 
determined from the below mentioned formula:  
                          
 
6. Percentage elongation break test: 
Percentage elongation is determined by measuring 
the length just before the breaking point. The 
percentage elongation can be determined from the 
below mentioned formula:  
                   
Where; 
L1 = final length of each strip. 
L2 = initial length of each strip. 
7. Drug content:  
The film of 2 cm2 was cut into small pieces and taken 
into 100ml volumetric flask containing 20ml 
methanol. This methanolic solution was diluted with 
phosphate buffer pH 7.4 up to 100ml. the solution 
was filtered through whatmann filter paper and the 
drug content was determined on UV 
spectrophotometer at λmax 275nm after suitable 
dilutions. 
8. In-vitro drug release studies: 
 The in-vitro drug release studies were carried out in 
a Franz diffusion cell. The cellulose acetate 
membrane (pore size = 0.45µm) was mounted 
between donor and the receptor compartment of the 
diffusion cell. The transdermal film was placed on 
the cellulose acetate membrane and covered with 
aluminum foil. The receptor compartment was filled 
with freshly prepared phosphate buffer pH 7.4 
(55ml). The whole assembly was fixed on a magnetic 
stirrer with hot plate apparatus. The solution in 
receptor compartment was stirred at 35-45 rpm and 
temperature was maintained at 32±0.5ºC. Sample 
(3ml) was withdrawn at different interval and 
replaced with the same volume of the phosphate 
buffer pH7.4. Samples were analyzed 
spectrophotometrically at 275nm. 
9. Skin irritation study for F1: 
Skin irritation testing can be performed on the 
healthy Albino rabbits weighing between 1.2-2.5 kg. 
Remove the hair from the dorsal surface and clean 
the dorsal surface using rectified spirit. Aqueous 
solution of formalin 0.8% was used as a standard 
irritant. Prepared transdermal patches of area 15 cm2 
were used as test patches. 0.8% of formalin solution 
was applied in the right dorsal surface of each rabbits 
whereas test patches were applied on the left dorsal 
surface. The patches were removed after 24 hours 
and skin was examined. 
BATCH 
CODE 
INGREDIENTS 
HPMC 
5 cps 
(mg) 
HPMC 15 
cps 
(mg) 
HPMC K 100M 
(mg) 
EC 
(mg) 
PVP K30 
(mg) 
ERS 
100 
(mg) 
PG 
(mg) 
PEG 
400 
(ml) 
n-DB 
(ml) 
F1 460 - - 840 - - 208 0.3 0.3 
F2 1070 - - - 230 - 208 0.3 0.3 
F3 650 - - 650 - - 208 0.3 0.3 
F4 500 - - 800 - - 208 0.6 - 
F5 980 - - - 320 - 208 - 0.6 
F6 - 460 - 840 - - 208 0.2 0.4 
F7 - 650 - 650 - - 208 0.4 0.2 
F8 - 500 - 800 - - 208 0.1 0.5 
F9 460 - - - - 840 208 0.26 0.26 
F10 650 - - - - 650 208 0.26 0.26 
F11 - - 650 650 - - 208 0.3 0.3 
F12 - - 450 850 - - 208 0.2 0.4 
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Table 2: Physicochemical evaluation parameters 
 
Batch 
Code 
PARAMETERS 
Weight Variation 
(Mean (mg) ± SD) 
Thickness 
(Mean (mm)± SD) 
Moisture CONTENT 
(Weight %) 
Water Absorption (Weight %) 
75% RH 93% RH 
F1 365 ± 2.06 0.15 ± 0.021 1.12 1.79 2.09 
F2 364 ± 4.02 0.14 ± 0.029 1.13 1.81 2.32 
F3 358 ± 3012 0.20 ± 0.031 1.18 2.02 2.82 
F4 354 ± 3.41 0.17 ± 0.020 1.14 2.55 2.73 
F5 357 ± 5.11 0.15 ± 0.015 1.18 3.01 3.45 
F6 359 ± 3.91 0.19 ± 0.018 1.23 3.52 3.79 
F7 351 ± 2.98 0.16 ± 0.040 1.14 1.92 2.18 
F8 361 ± 5.03 0.18 ± 0.025 1.18 3.30 3.64 
F9 367 ± 4.08 0.15 ± 0.013 1.19 3.39 3.65 
F10 362 ± 5.09 0.19 ± 0.025 1.20 3.42 3.71 
F11 342 ± 3.58 0.20 ± 0.023 1.23 3.68 3.89 
F12 341 ± 3.59 0.18 ± 0.019 1.25 3.78 3.97 
Table 3: Evaluation parameters 
BATCH 
CODES 
PARAMETERS 
FOLDING 
ENDURANCE 
% Elongation break 
test 
% drug content % cumulative drug 
release 
F1 210 ± 5.2 40.2 ± 0.012 99.38 ± 4.02 55.87 ± 0.009 
F2 212 ± 3.2 41.8 ± 0.014 97.02 ± 3.32 40.37 ± 0.010 
F3 200 ± 7.3 39.7 ± 0.012 99.02 ± 5.22 51.14 ± 0.044 
F4 198 ± 3.9 35.8 ± 0.016 96.91 ± 4.13 49.38 ± 0.097 
F5 215 ± 5.5 41.9 ± 0.011 98.83 ± 5.91 38.31 ± 0.021 
F6 210 ± 7.6 36.2 ± 0.017 96.79 ± 3.51 45.16 ± 0.014 
F7 204 ± 7.1 32.1 ± 0.13 97.18 ± 2.99 42.58 ± 0.029 
F8 211 ± 3.8 31.3 ± 0.15 98.23 ± 3.12 43.31 ± 0.032 
F9 217 ± 4.1 42.1 ± 0.11 99.17 ± 4.72 45.31 ± 0.029 
F10 214 ± 7.7 40.3 ± 0.19 99.03 ± 4.18 46.43 ± 0.078 
F11 208 ± 4.3 33.2 ± 0.13 98.02 ± 5.02 31.46 ± 0.096 
F12 212 ± 5.3 34.09 ± 0.14 98.09 ± 6.01 30.59 ± 0.057 
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Figure 1: In vitro release profile of Glipizide patches (F1 to F4): 
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Figure 2: in vitro release profiles (F5 to F8) 
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Figure 3:  In vitro release profiles (F9 to F12) 
RESULTS AND DISCUSSION: 
Transdermal patches of Glipizide were prepared by solvent 
evaporation method in a Petri-dish on a mercury platform 
with an inverted funnel to control the rate of evaporation 
of the solvent. Different formulation (as shown in table 1) 
containing Glipizide were prepared to achieve the sustain 
release pattern within the therapeutic range. 
3.1 Investigation of drug-polymer compatibility: 
Drug - polymer compatibility was checked by comparing 
the IR spectra of formulations with that of the pure drug. 
No significant changes in the functional groups between 
the two spectra were observed. This ensured the 
compatibility of polymer with that of the drug. 
3.2 Transparency: 
Patches prepared from HPMC-PVP had maximum 
transparency, followed by HPMC-EC and HPMC –ERS. 
 
3.3 Physicochemical evaluation of transdermal patches: 
The results of the physicochemical evaluation of the 
transdermal patches are described in table 2 and table 3. 
The weight variation of all the formulations varied in 
between 351 ± 2.98 and 365 ± 2.06. The variation in the 
thickness of all the formulation was in the range 0.14 ± 
0.029 to 0.20 ± 0.031. Moisture content of these patches 
was found to vary from 1.12 to 1.25. Water absorption at 
75%RH and 93%RH was observed from 1.79 to 3.78 and 
2.09 to 3.97 respectively. This difference in the moisture 
content and water absorption was may be due to the 
difference in hydrophilicity of the polymers and extent of 
solvent evaporation during formulation. Folding endurance 
was found to be in between 180 ± 7.7 and 217 ± 4.1. The 
% elongation break test was found to be from 31.3 ± 0.15 
to 42.1 ± 0.11. Folding endurance and % elongation break 
test was found maximum in formulation containing 
Eudragit RS 100 and PVP K 30 as polymers. The % drug 
content and % cumulative drug release was found 
maximum in formulation F1 (batch code).
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Figure 4: IR spectra of Glipizide 
 
Figure 5: IR spectra of mixture of Glipizide, HPMC 5 cps and Ethyl cellulose 
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Figure 6: IR spectra of mixture of Glipizide, HPMC 5 cps and PVP K 30 
 
Figure 7: IR spectra of mixture of Glipizide, HPMC K 100 and Ethyl cellulose 
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Figure 8: IR spectra of mixture of Glipizide, HPMC 5 cps and Eudragit RS 100 
3.4 In-vitro release studies:  
In-vitro release studies for all the prepared patches were 
carried out for 12 hours. % cumulative drug release after 12 
hours was taken and compared for all the patches. F1 
exhibited maximum drug release at the end of 12th hour. 
Results are as shown in the table. 
3.5 Skin irritation study: 
Based on physicochemical evaluation and in-vitro release 
rate studies, F1 was selected for skin irritation test. Skin 
irritation test was performed on albino rabbits. No signs of 
erythema or redness were observed for 24 hours after the 
application of the patch. 
DISCUSSION: 
IR studies revealed that the drug and polymer were 
compatible with each other. Of all the batches prepared and 
evaluated, F1 showed promising results.  It was concluded 
that HPMC 5 cps and ethyl cellulose are useful in 
formulating sustained release patches. Moreover, patches 
prepared from HPMC 5cps and EC (batch code = F1) 
exhibited better in-vitro drug release-time profile. Also, 
amongst the two plasticizers used alone and in various 
combinations, batch F9, F5 and F1 produced patches that 
exhibited high folding endurance and good manageable 
characteristics. Detailed investigations on in-vivo studies 
needs to be carried out and an in vivo- in vitro correlation 
need to be established to ensure the efficiency and 
bioavailability of the formulation. 
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